Table 3 Comparison of CS and WW groups with respect to the changes of pulmonary function
From: The effectiveness of glucocorticoid treatment in post-COVID-19 pulmonary involvement
CS group (N = 131) | WW group (N=894a) | Mean difference | p-valueb | |
|---|---|---|---|---|
(mean ± SD) | (mean ± SD) | (MD ± SD) | ||
ΔVC [ml] | 403.7 ± 510.05 | 95.1 ± 353.23 | 308.59 ± 46.10 | <0.0001 |
ΔVC [%predicted] | 10.3 ± 13.33 | 2.7 ± 9.94 | 7.62 ± 1.21 | <0.0001 |
ΔFEV1/VC [%] | -0.9 ± 5.23 | -0.7 ± 4.71 | -0.19 ± 0.48 | 0,1594 |
ΔTLC [ml] | 649.8 ± 756.45 | 92.7 ± 758.67 | 557.13 ± 70.79 | <0.0001 |
ΔTLC [%predicted] | 9.9 ± 12.16 | 1.3 ± 12.84 | 8.68 ± 1.15 | <0.0001 |
ΔRV [ml] | 204.7 ± 700.12 | 22.2 ± 611.47 | 182.51 ± 64.50 | 0,0013 |
ΔRV [%predicted] | 8.4 ± 29.19 | 0.2 ± 29.61 | 8.19 ± 2.74 | 0,003 |
ΔDLCOc [%predicted) | 10.2 ± 12.55 | 2.8 ± 12.82 | 7.39 ± 1.18 | <0.0001 |
ΔKCOc [%predicted] | 4.4 ± 11.85 | 1.5 ± 10.01 | 2.92 ± 1.09 | 0,0564 |